We operate a high-throughput system for identifying and assessing the market and intellectual property (IP) landscape of proven products. This enables us to select projects with the best risk/reward profile.
Small Pharma’s development mechanism generates a continuous flow of potential projects. These are sourced through detailed analysis of thousands of known active ingredients.
The selection process comprises specific criteria, chosen to efficiently implement our strategy. Each of these criteria is a de-risking parameter designed to maximise our chances of successfully delivering improved pharmaceutical products.
Our multi-project output allows us to select projects with the greatest prospects of low risk and significant patient value. We aim to develop one new product each year.